Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

A Randomized Clinical Trial Evaluating the Benefits of Doxorubicin Chemoembolization Versus Systemic Doxorubicin in Patients With Unresectable, Advanced Hepatocellular Carcinoma

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping the cells from dividing. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. It is not yet known whether doxorubicin is more effective with or without chemoembolization in treating unresectable hepatocellular carcinoma (liver cancer).

PURPOSE: This randomized phase III trial is studying doxorubicin given by infusion to see how well it works compared to doxorubicin given by chemoembolization in treating patients with advanced liver cancer than cannot be removed by surgery.

Study Overview

• Status: Unknown
• Conditions: Liver Cancer
• Intervention / Treatment: Drug: doxorubicin hydrochloride; Procedure: hepatic artery embolization

Detailed Description

OBJECTIVES:

Primary

• Compare the survival of patients with advanced unresectable primary hepatocellular carcinoma treated with intravenous doxorubicin hydrochloride vs doxorubicin hydrochloride chemoembolization.

Secondary

• Compare the response rate in patients treated with these regimens.
• Compare time to progression in patients treated with these regimens.
• Compare the toxicity of these regimens in these patients.
• Compare the quality of life of patients treated with these regimens.
• Compare the health economic implications of these regimens in these patients.

OUTLINE: This is a randomized, controlled, multicenter study. Patients are stratified according to participating center, stage of disease, and alpha-fetoprotein levels (< 500 ng/mL vs ≥ 500 ng/mL). Patients are randomized to 1 of 2 treatment arms.

• Arm I (control arm): Patients receive doxorubicin hydrochloride IV over 3-5 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
• Arm II (chemoembolization arm): Patients undergo transarterial chemoembolization using DC Bead and doxorubicin hydrochloride. Chemoembolization repeats every 8 weeks for a total of 3 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline and at weeks 10 and 24.

Patients are followed at 4 weeks and then every 12 weeks thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 280 patients (140 per treatment arm) will be accrued for this study.

• Study Type: Interventional
• Enrollment (Anticipated): 280
• Phase: Phase 3

Contacts and Locations

Study Locations

• United Kingdom
  • England
    • Birmingham, England, United Kingdom, B15 2TT
      • Cancer Research UK Clinical Trials Unit - Birmingham
    • Bristol, England, United Kingdom, BS2 8HW
      • Bristol Haematology and Oncology centre
    • Cambridge, England, United Kingdom, CB2 2QQ
      • Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust
    • Liverpool, England, United Kingdom, L69 3GA
      • Royal Liverpool University Hospital
    • London, England, United Kingdom, W12 OHS
      • Hammersmith Hospital
    • Newcastle-Upon-Tyne, England, United Kingdom, NE7 7DN
      • Freeman Hospital
    • Southampton, England, United Kingdom, SO14 0YG
      • Royal South Hants Hospital
  • Scotland
    • Edinburgh, Scotland, United Kingdom, EH16 4SA
      • Royal Infirmary of Edinburgh at Little France
    • Edinburgh, Scotland, United Kingdom, EH3 9YW
      • Royal Infirmary Edinburgh
    • Glasgow, Scotland, United Kingdom, G11 6NT
      • West of Scotland Cancer Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed hepatocellular carcinoma (HCC)

  • Advanced, unresectable disease
• No clinically significant ascites
• No modified Child-Pugh class C liver disease
• No main portal vein occlusion/involvement
• No extrahepatic tumor of any kind

PATIENT CHARACTERISTICS:

Age

• 18 and over (16 and over for patients residing in Scotland)

Performance status

• ECOG 0-2

Life expectancy

• More than 3 months

Hematopoietic

• Absolute neutrophil count ≥ 1,500/mm^3
• Hemoglobin ≥ 8.5 g/dL
• Platelet count ≥ 100,000/mm^3

Hepatic

• Bilirubin < 5.0 mg/dL
• Transaminases < 2.5 times upper limit of normal (ULN)
• INR < 1.5

Renal

• Creatinine < 2 times ULN

Cardiovascular

• No New York Heart Association class III or IV cardiac disease
• No acute angina
• No significant peripheral vascular disease
• No thrombosis of main portal vein
• LVEF ≥ 50%

Other

• Not pregnant or nursing
• Fertile patients must use effective contraception
• No other concurrent serious medical condition
• No serious infection
• No psychological, familial, sociological, or geographical factors that would preclude study compliance
• No other malignancy within the past 5 years except carcinoma in situ of the cervix or non-melanoma skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No prior biologic therapy for advanced unresectable HCC

Chemotherapy

• No prior systemic or regional chemotherapy
• No prior chemotherapy for advanced unresectable HCC
• No other concurrent anticancer chemotherapy

Endocrine therapy

• No prior hormonal therapy for advanced unresectable HCC

Radiotherapy

• No prior radiotherapy for advanced unresectable HCC
• No other concurrent anticancer radiotherapy

Surgery

• More than 7 days since prior major surgery
• More than 3 days since prior laparoscopy

Other

• More than 4 weeks since prior investigational agents
• More than 6 weeks since prior ablative therapy and must have radiological evidence of progression if ablated site is the only site of disease
• No other concurrent investigational agents

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Overall survival

Secondary Outcome Measures

Outcome Measure
Toxicity
Overall response
Quality of life as assessed by EORTC QOL QLQ-30 and EORTC QLQ HCC18 at baseline and 10 and 24 weeks
Time to progression as assessed by RECIST criteria
Health economics
Proteomic and immunological analysis

Collaborators and Investigators

• Sponsor: University Hospital Birmingham
• Investigators: Study Chair: O. J. Garden, Royal Infirmary of Edinburgh at Little France

Study record dates

Study Major Dates

• Study Start: April 1, 2004

Study Registration Dates

• First Submitted: March 8, 2004
• First Submitted That Met QC Criteria: March 8, 2004
• First Posted (Estimate): March 9, 2004

Study Record Updates

• Last Update Posted (Estimate): December 18, 2013
• Last Update Submitted That Met QC Criteria: December 17, 2013
• Last Verified: May 1, 2007

More Information

Terms related to this study

• Keywords: advanced adult primary liver cancer; adult primary hepatocellular carcinoma
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Liver Diseases; Carcinoma; Carcinoma, Hepatocellular; Liver Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antibiotics, Antineoplastic; Doxorubicin; Liposomal doxorubicin
• Other Study ID Numbers: CDR0000353298; CRUK-HEP-1; EU-20340; ISRCTN78345798